000128707 001__ 128707
000128707 005__ 20240228143343.0
000128707 0247_ $$2doi$$a10.1111/jnc.13532
000128707 0247_ $$2pmid$$apmid:26756400
000128707 0247_ $$2ISSN$$a0022-3042
000128707 0247_ $$2ISSN$$a1471-4159
000128707 0247_ $$2altmetric$$aaltmetric:4987449
000128707 037__ $$aDKFZ-2017-04722
000128707 041__ $$aeng
000128707 082__ $$a610
000128707 1001_ $$0P:(DE-He78)77839d5cf53d09e62bdfca3d3172fab1$$aHannan, Shabab Bin$$b0$$eFirst author$$udkfz
000128707 245__ $$aCellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
000128707 260__ $$aOxford$$bWiley-Blackwell$$c2016
000128707 3367_ $$2DRIVER$$aarticle
000128707 3367_ $$2DataCite$$aOutput Types/Journal article
000128707 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521800811_15295
000128707 3367_ $$2BibTeX$$aARTICLE
000128707 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128707 3367_ $$00$$2EndNote$$aJournal Article
000128707 520__ $$aAbnormal tau accumulations were observed and documented in post-mortem brains of patients affected by Alzheimer's disease (AD) long before the identification of mutations in the Microtubule-associated protein tau (MAPT) gene, encoding the tau protein, in a different neurodegenerative disease called Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). The discovery of mutations in the MAPT gene associated with FTDP-17 highlighted that dysfunctions in tau alone are sufficient to cause neurodegeneration. Invertebrate models have been diligently utilized in investigating tauopathies, contributing to the understanding of cellular and molecular pathways involved in disease etiology. An important discovery came with the demonstration that over-expression of human tau in Drosophila leads to premature mortality and neuronal dysfunction including neurodegeneration, recapitulating some key neuropathological features of the human disease. The simplicity of handling invertebrate models combined with the availability of a diverse range of experimental resources make these models, in particular Drosophila a powerful invertebrate screening tool. Consequently, several large-scale screens have been performed using Drosophila, to identify modifiers of tau toxicity. The screens have revealed not only common cellular and molecular pathways, but in some instances the same modifier has been independently identified in two or more screens suggesting a possible role for these modifiers in regulating tau toxicity. The purpose of this review is to discuss the genetic modifier screens on tauopathies performed in Drosophila and C. elegans models, and to highlight the common cellular and molecular pathways that have emerged from these studies. Here, we summarize results of tau toxicity screens providing mechanistic insights into pathological alterations in tauopathies. Key pathways or modifiers that have been identified are associated with a broad range of processes including, but not limited to, phosphorylation, cytoskeleton organization, axonal transport, regulation of cellular proteostasis, transcription, RNA metabolism, cell cycle regulation, and apoptosis. We discuss the utility and application of invertebrate models in elucidating the cellular and molecular functions of novel and uncharacterized disease modifiers identified in large-scale screens as well as for investigating the function of genes identified as risk factors in genome-wide association studies from human patients in the post-genomic era. In this review, we combined and summarized several large-scale modifier screens performed in invertebrate models to identify modifiers of tau toxicity. A summary of the screens show that diverse cellular processes are implicated in the modification of tau toxicity. Kinases and phosphatases are the most predominant class of modifiers followed by components required for cellular proteostasis and axonal transport and cytoskeleton elements.
000128707 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000128707 588__ $$aDataset connected to CrossRef, PubMed,
000128707 650_7 $$2NLM Chemicals$$aMAPT protein, human
000128707 650_7 $$2NLM Chemicals$$aRecombinant Fusion Proteins
000128707 650_7 $$2NLM Chemicals$$atau Proteins
000128707 7001_ $$0P:(DE-He78)44dc011368b331679dbc8d341ae41420$$aDräger, Nina$$b1$$udkfz
000128707 7001_ $$0P:(DE-He78)e9a603e8a132f8501ed78cf4995c246c$$aRasse, Tobias$$b2$$udkfz
000128707 7001_ $$aVoigt, Aaron$$b3
000128707 7001_ $$0P:(DE-He78)813a306749dc9a24333a77867a42bbd9$$aJahn, Thomas$$b4$$eLast author$$udkfz
000128707 773__ $$0PERI:(DE-600)2020528-4$$a10.1111/jnc.13532$$gVol. 137, no. 1, p. 12 - 25$$n1$$p12 - 25$$tJournal of neurochemistry$$v137$$x0022-3042$$y2016
000128707 909CO $$ooai:inrepo02.dkfz.de:128707$$pVDB
000128707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77839d5cf53d09e62bdfca3d3172fab1$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)44dc011368b331679dbc8d341ae41420$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e9a603e8a132f8501ed78cf4995c246c$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128707 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)813a306749dc9a24333a77867a42bbd9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128707 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000128707 9141_ $$y2016
000128707 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128707 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROCHEM : 2015
000128707 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128707 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128707 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128707 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128707 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128707 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128707 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128707 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128707 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128707 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128707 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128707 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128707 9201_ $$0I:(DE-He78)B180-20160331$$kB180$$lProteostase neurodegenerativer Erkrankungen$$x0
000128707 980__ $$ajournal
000128707 980__ $$aVDB
000128707 980__ $$aI:(DE-He78)B180-20160331
000128707 980__ $$aUNRESTRICTED